EcoR1 Capital’s Spero Therapeutics SPRO Stock Holding History

EcoR1 Capital’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-892,741	Closed	-$9.38M	–	60
2018 Q3	$9.38M	Buy	+892,741	New	+$10.4M	0.85%	28

Other funds holding SPRO

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital's SPRO Position: Q4 2018 in Review

EcoR1 Capital sold out of Spero Therapeutics (SPRO) in Q4 2018, closing a stake of 892,741 shares — an estimated $9.38M sold.

EcoR1 Capital first reported a position in SPRO in Q3 2018 and held it in 1 quarter. The position peaked at $9.38M in Q3 2018. 52 funds tracked by Wall St. Rank hold SPRO as of Q4 2018.

EcoR1 Capital reported no remaining Spero Therapeutics position as of Q4 2018 after selling out during the quarter.
EcoR1 Capital sold 892,741 Spero Therapeutics shares in Q4 2018, an estimated $9.38M.
EcoR1 Capital first reported a position in Spero Therapeutics in Q3 2018 and held it in 1 quarter.
EcoR1 Capital's Spero Therapeutics position peaked at $9.38M in Q3 2018.
52 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2018.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.